NTRK3 and retinitis pigmentosa: The anti-TrkC.T1 mAbs may be developed further as antagonists or may be used to eliminate TrkC.T1-expressing cells (which produce TNF-α) at the onset of degenerative diseases such as glaucoma, retinitis pigmentosa, and ALS (Saragovi et al., 2019) (e.g., Müller glial cells in the retina or activated glia in spinal cord).